Supplementary Appendix

Optum® De-Identified COVID-19 Electronic Health Record Dataset

The Optum de-identified COVID-19 Electronic Health Record (EHR) dataset is a subset of the Optum EHR data, which is reflective of the demographic distribution by age and sex of the US population.^{1,2} The database is certified as de-identified and is therefore exempt from institutional review board approval.² De-identified clinical data from numerous health plans, providers, and payers (ie, public, commercial, other types, uninsured) are included, which is integrated across care settings and are longitudinally linked by patient.^{1,2} Inclusion of data from 2007 in the Optum COVID-19 EHR database allows analysis of patient medical history.¹ A limitation of the Optum COVID-19 EHR database is that it may not capture records outside of the integrated delivery network and death events are recorded at the month level, to reduce the risk of patient identifiability.²

Characteristics or Underlying Medical Conditions Associated with Increased Risk of Developing Severe COVID-19

Patients had to have ≥ 1 of the following characteristics or underlying medical conditions associated with increased risk of developing severe COVID-19 at baseline unless otherwise specified: age ≥ 60 years at index date; body mass index >25 kg/m²; current smoker; immunosuppressive disease or prolonged use of immune-weakening medications; chronic lung disease, hypertension, cardiovascular disease, diabetes mellitus, chronic kidney disease, sickle cell disease, neurodevelopmental disorders or other medically complex conditions; or cancer diagnosis (other than localized skin cancer) ≤ 1 year before the index date. Patients were excluded if they had any of the following high-risk criteria at any time before the index date (unless specified otherwise): known medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic or active hepatitis B or C infection, primary biliary cirrhosis, or acute liver failure; dialysis receipt or end stage of renal disease; or pregnant or lactating within 9 months before index date.

¹ Curtis JR et al. J Rheumatol. 2022;49:320-329.

² Page JH et al. BMJ Open. 2022;12:e055137.

COVID-19 Treatments or Contraindicated Medications

Patients in both groups were excluded if they had taken any of the following medications within 28 days

COVID-19 treatments in use or recommended at the time of the study ³	Contraindicated medications		
Anti-SARS-CoV-2 antibody products	Alpha1-adrenoreceptor antagonist	HMG-CoA reductase inhibitors	
Bamlanivimab/etesevimab	Alfuzosin	Lovastatin	
Casirivimab/imdevimab	Analgesics	Simvastatin	
Sotrovimab	Pethidine	PDE5 inhibitor	
Tixagevimab/cilgavimab	Propoxyphene	Sildenafil	
Bebtelovimab	Antianginal	Sedative/hypnotics	
Convalescent plasma	Ranolazine	Triazolam	
Antiviral therapy	Antiarrhythmic	Oral midazolam	
Remdesivir	Amiodarone	Anticancer drugs	
Molnupiravir	Dronedarone	Apalutamide	
Chloroquine/hydroxychloroquine	Flecainide	Anticonvulsant	
Azithromycin	Propafenone	Carbamazepine	
Lopinavir/ritonavir	Quinidine	Phenobarbital	
Ivermectin	Anti-gout	Phenytoin	
Nitazoxanide	Colchicine	Herbal products	
Ribavirin	Antipsychotics	St. John's Wort	
Interferon-beta	Clozapine		
Immunomodulators	Pimozide		
Systemic corticosteroids	Lurasidone		
Dexamethasone	Interleukin inhibitors		
Methylprednisolone	Tocilizumab		
Fluvoxamine	Sarilumab		
Antimycobacterials	Ergot derivatives		
Rifampin	Ergotamine		
Antithrombotic therapy	Methylergonovine		
Heparin	Dihydroergotamine		

of index date:

³ NIH Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Last update: April 1, 2022. Accessed on: April 24, 2022. <u>https://files.covid19treatmentguidelines.nih.gov/guidelines/archive/covid19treatmentguidelines-04-01-2022.pdf</u>.

Prescription Time Distribution Method

Index dates were assigned to individuals in the non-nirmatrelvir/ritonavir group using the Prescription Time Distribution Method (PTDM)⁴ as follows. Among all patients in the nirmatrelvir/ritonavir group with a date of confirmed COVID-19 diagnosis, the time from the date of confirmed COVID-19 to the date of nirmatrelvir/ritonavir prescription was calculated. The percentages of those prescribed nirmatrelvir/ritonavir on Day 0 (date of COVID-19 diagnosis), and Days 1, 2, 3, and 4 were calculated. Patients in the non-nirmatrelvir/ritonavir group were randomly assigned index dates relative to their COVID-19 diagnosis dates based on the resulting distribution of the index date in the nirmatrelvir/ritonavir group. For example, if 20% of nirmatrelvir/ritonavir patients were prescribed nirmatrelvir/ritonavir on Day 1 relative to their confirmed COVID-19 diagnosis, then 20% of nonnirmatrelvir/ritonavir patients were randomly selected and assigned their index date to be the date of COVID-19 diagnosis plus 1 day.

Algorithm for Assigning Date of Death

In the Optum database, deaths are recorded by month and year and not by exact date. The following algorithm was applied to assign a death date to each patient who died during follow-up:

- 1) Assign 15th day of the month as the death date;
- If death occurred before the index date but on the same month, assign a death date of the last day of the month of death;
- 3) If death occurred after the end of follow-up but on the same month, assign the death date to be the same as the follow-up end date and consider this patient to have died in the study.

Loss to Follow-up

For any patient in the database, the last active date was derived from the last date of any healthcare activity (eg, outpatient, inpatient, emergency room, prescription, laboratory value). If a patient had the last active date before the end of the 30-day follow-up window (primary analysis), without hospitalization, this patient was considered lost to follow-up in the analysis. Overall, 1339 (48%) and 4686 (43%) patients in the nirmatrelvir/ritonavir and non-nirmatrelvir/ritonavir groups, respectively, had their last active date before the end of the 30-day window and were considered lost to follow-up.

⁴ Zhou Z et al. Am J Epidemiol 2005;162:1016-1023.

Corresponding values before the end of the 15-day window were 938 (33%) and 3345 (31%) patients in the nirmatrelvir/ritonavir and non-nirmatrelvir/ritonavir groups, respectively. Since Optum COVID-19 EHR data are encounter-based and the study period is short (December 22, 2022 to June 8, 2022) loss to follow-up during the 30-day risk window for a patient shows that these patients had no additional healthcare utilization during those 30 days. It does not necessarily mean that this patient left the healthcare system; thus, the proportion of those lost to follow-up should be interpreted with caution.

	Before PSM					
	Nirmatrelvir/	Non-Nirmatrelvir/		Nirmatrelvir/	Non-Nirmatrelvir/	
	Ritonavir	Ritonavir	Standardized	Ritonavir	Ritonavir	Standardized
	N=2811	N=194,542	Difference	N=2808	N=10,849	Difference
Number of hospitalizations						
0	2624 (93.3)	179,547 (92.3)	0.041	2621 (93.3)	10,123 (93.3)	0.001
1	154 (5.5)	11,748 (6.0)	0.024	154 (5.5)	587 (5.4)	0.003
≥2	33 (1.2)	3247 (1.7)	0.042	33 (1.2)	139 (1.3)	0.009
Mean ± standard deviation	0.08 ± 0.34	0.10 ± 0.42	0.053	0.08 ± 0.34	0.09 ± 0.38	0.014
Length of stay, days						
Median, IQR	4.00, 7.00	4.00, 6.00	-	4.00, 7.00	4.00, 6.00	-
Emergency room visits						
0	2357 (83.8)	136,186 (70.0)	0.333	2354 (83.8)	9094 (83.8)	0.004
1	286 (10.2)	31,146 (16.0)	0.174	286 (10.2)	1130 (10.4)	0.005
≥2	168 (6.0)	27,210 (14.0)	0.270	168 (6.0)	625 (5.8)	0.013
Mean ± standard deviation	0.27 ± 0.79	0.65 ± 1.97	0.252	0.27 ± 0.79	0.29 ± 0.94	0.023
Physician office visits						
0	265 (9.4)	29,125 (15.0)	0.170	265 (9.4)	1058 (9.8)	0.002
1	335 (11.9)	23,626 (12.1)	0.007	335 (11.9)	1269 (11.7)	0.012
≥2	2211 (78.7)	141,791 (72.9)	0.135	2208 (78.6)	8522 (78.6)	0.008

Table S1. Healthcare utilization within 12 months before index date before and after PSM

	Mean ± standard deviation	6.78 ± 8.07	5.88 ± 7.74	0.113	6.77 ± 8.07	6.74 ± 7.92	0.008
Teler	nedicine visits						
	0	1287 (45.8)	95,571 (49.1)	0.067	1287 (45.8)	5023 (46.3)	0.006
	1	417 (14.8)	28,119 (14.5)	0.011	415 (14.8)	1561 (14.4)	0.012
	≥2	1107 (39.4)	70,852 (36.4)	0.061	1106 (39.4)	4265 (39.3)	0.002
	Mean ± standard deviation	2.79 ± 5.75	2.39 ± 4.88	0.074	2.79 ± 5.75	2.71 ± 5.25	0.003
Urgen	t care visits						
	0	2653 (94.4)	171,289 (88.0)	0.225	2650 (94.4)	10,225 (94.2)	0.001
	1	98 (3.5)	13,321 (6.8)	0.152	98 (3.5)	385 (3.5)	0.001
	≥2	60 (2.1)	9932 (5.1)	0.160	60 (2.1)	239 (2.2)	0.000
	Mean ± standard deviation	0.10 ± 0.57	0.23 ± 0.88	0.175	0.10 ± 0.57	0.10 ± 0.52	0.016

IQR, interquartile range; PSM=propensity score matching.

Values shown are n (%) unless otherwise specified.

	Before PSM			After PSM		
-	Nirmatrelvir/	Non-Nirmatrelvir/		Nirmatrelvir/	Non-Nirmatrelvir/	
	Ritonavir	Ritonavir	Standardized	Ritonavir	Ritonavir	Standardized
Comorbidity, n (%)	N=2811	N=194,542	Difference	N=2808	N=10,849	Difference
Multiple sclerosis	15 (0.5)	786 (0.4)	0.019	15 (0.5)	54 (0.5)	0.005
Sjögren's syndrome	19 (0.7)	615 (0.3)	0.051	19 (0.7)	52 (0.5)	0.025
Guillain-Barré	1 (0.0)	51 (0.0)	0.005	1 (0.0)	6 (0.1)	0.008
Idiopathic thrombocytopenia purpura	0 (0.0)	175 (0.1)	-	0 (0.0)	10 (0.1)	-
Autoimmune thyroiditis	43 (1.5)	1763 (0.9)	0.057	43 (1.5)	127 (1.2)	0.031
Giant cell arteritis	0 (0.0)	56 (0.0)	-	0 (0.0)	8 (0.1)	-
Psoriasis	62 (2.2)	1920 (1.0)	0.097	62 (2.2)	153 (1.4)	0.057
Systemic or cutaneous lupus erythematosus	29 (1.0)	892 (0.5)	0.067	29 (1.0)	60 (0.6)	0.054
Autoimmune arthritis/rheumatoid arthritis	73 (2.6)	2506 (1.3)	0.095	73 (2.6)	211 (1.9)	0.043
Interstitial lung disease	43 (1.5)	1400 (0.7)	0.077	43 (1.5)	127 (1.2)	0.032
Cardiomyopathies	50 (1.8)	2633 (1.4)	0.034	50 (1.8)	209 (1.9)	0.012

Table S2. Baseline clinical characteristics before and after PSM reported in <5% in both groups</th>

Cerebrovascular disease or							
stroke (including transient	130 (4.6)	6415 (3.3)	0.068	130 (4.6)	529 (4.9)	0.015	
ischemic attack)							
HIV infection	20 (0.7)	701 (0.4)	0.048	20 (0.7)	41 (0.4)	0.047	
Sickle cell disease	4 (0.1)	341 (0.2)	0.008	4 (0.1)	3 (0.0)	0.038	

PSM=propensity score matching.

Values shown are n (%).

	Hospitalization	within 30 days	Hospitalization	within 15 days
			Non-	
	Nirmatrelvir/Ritonavir	Nirmatrelvir/Ritonavir	Nirmatrelvir/Ritonavir	Nirmatrelvir/Ritonavir
Race				
White				
Patients at risk	2381	9132	2381	9132
Events	24	634	14	595
Incidence proportion, % (95% CI)	1.01 (0.65, 1.50)	6.94 (6.43, 7.48)	0.59 (0.32, 0.98)	6.52 (6.02, 7.04)
Person-days	47,277	172,909	26,844	97,181
Incidence rate, per 100 person-days (95% CI)	0.05 (0.03, 0.08)	0.37 (0.34, 0.40)	0.05, (0.03, 0.09)	0.61 (0.56, 0.66)
Hazard ratio (95% CI)	0.14 (0.09, 0.21)	-	0.09 (0.05, 0.15)	-
Relative risk reduction, % (95% CI)	86 (79, 81)	-	91 (85, 95)	-
African American ^a				
Patients at risk	167	662	167	662
Events	8	58	7	56
Incidence proportion, % (95% CI)	4.79 (2.09, 9.22)	8.76 (6.72, 11.18)	4.19 (1.70, 8.45)	8.46 (6.45, 10.84)
Person-days	3504	11,813	1987	6653
Incidence rate, per 100 person-days (95% Cl)	0.23 (0.10, 0.45)	0.49 (0.37, 0.63)	0.35 (0.14, 0.73)	0.84 (0.64, 1.09)

Table S3. Hospitalization among subgroups of patients with COVID-19 by nirmatrelvir/ritonavir prescription status after PSM

Hazard ratio (95% CI)	0.35 (0.15, 0.83)	-	0.33 (0.13, 0.83)	-
Relative risk reduction, % (95% CI)	65 (17, 85)	-	67 (17, 87)	-
Age				
≥65 years ^b				
Patients at risk	1250	4723	1250	4723
Events	26	583	16	555
Incidence proportion, % (95% CI)	2.08 (1.36, 3.03)	12.34 (11.42, 13.32)	1.28 (0.73, 2.07)	11.75 (10.85, 12.70)
Person-days	25,399	84,908	14,315	48,069
Incidence rate, per 100 person-days (95% CI)	0.10 (0.07, 0.15)	0.69 (0.63, 0.74)	0.11 (0.06, 0.18)	1.16 (1.06, 1.25)
Hazard ratio (95% CI)	0.17 (0.12, 0.26)	-	0.11 (0.07, 0.19)	-
Relative risk reduction, % (95% CI)	83 (74, 88)	-	89 (91, 93)	-
<65 years ^c				
Patients at risk	1558	6126	1558	6126
Events	8	169	6	153
Incidence proportion, % (95% CI)	0.51 (0.22, 1.01)	2.76 (2.36, 3.20)	0.39 (0.14, 0.84)	2.50 (2.12, 2.92)
Person-days	30,562	120,072	17,406	67,027
Incidence rate, per 100 person-days (95% CI)	0.03 (0.01, 0.05)	0.14 (0.12, 0.16)	0.03 (0.01, 0.08)	0.23 (0.19 0.27)
Hazard ratio (95% CI)	0.19 (0.09, 0.38)	-	0.16 (0.07, 0.35)	-
Relative risk reduction, % (95% Cl)	81 (62, 91)	-	84 (65, 93)	-

Vaccination status

Vaccinated

Patients at risk	1897	7207	1897	7207
Events	20	412	11	380
Incidence proportion, % (95% CI)	1.05 (0.65, 1.62)	5.72 (5.19, 6.28)	0.58 (0.29, 1.04)	5.27 (4.77, 5.81)
Person-days	39,052	146,112	22,078	81,280
Incidence rate, per 100 person-days (95% CI)	0.05 (0.03, 0.08)	0.28 (0.26, 0.31)	0.05 (0.02, 0.09)	0.47 (0.42, 0.52)
Hazard ratio (95% CI)	0.18 (0.12, 0.28)	-	0.11 (0.06, 0.20)	-
Relative risk reduction, % (95% CI)	82 (72, 88)	-	89 (80, 94)	-

COPD=chronic obstruction pulmonary disease; ILD=interstitial lung disease; PSM=propensity score matching.

Hazard ratios and 95% CIs were computed using Cox proportional hazards regressions models. Relative risk reductions were derived by subtracting the hazard ratios from 1.

^aThe covariates of cohort month/year, age, ethnicity, insurance, medical history of autoimmune arthritis/rheumatoid arthritis, COPD, ILD, hypertension, HIV infection, smoking, diabetes, cancer, sickle cell disease, emergency room visits, and telemedicine visits were adjusted in the model among African American patients.

^bThe covariates of age (continuous), hypertension, and chronic kidney disease were adjusted in the model among ≥65-year-old patients. ^cThe covariates of cohort month/year and medical history of autoimmune arthritis/rheumatoid arthritis were adjusted in the model among <65year-old patients.

Figure S1. Hospitalization by month: all patients

Blue bars represent hospitalization rates for all Optum patients with COVID-19 meeting study eligibility criteria and having index dates between December 22, 2021 and May 8, 2022. Black bars represent published CDC COVID-19 hospitalization rates during the same time period.⁵

CDC=US Centers for Disease Control and Prevention.



⁵ US Centers for Disease Control and Prevention. COVID-19 Case Surveillance Public Use Data with Geography. Available at: https://data.cdc.gov/Case-Surveillance/COVID-19-Case-Surveillance-Public-Use-Data-with-Ge/n8mcb4w4. Accessed July 22, 2022.